Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00083252 · ClinicalTrials.gov registry record · Phase 2

Study of Talabostat and Cisplatin in Advanced Melanoma

A Phase 2 study of Melanoma and Skin Cancer, sponsored by Point Therapeutics.

Completed
Registry status
Phase 2
Development phase
13
Study locations

NCT00083252: Completed Phase 2 study of Melanoma and Skin Cancer, sponsored by Point Therapeutics.

NCT00083252 is a Phase 2 study of Melanoma and Skin Cancer that has completed, run by Point Therapeutics. The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00083252, a Phase 2 study of Melanoma and Skin Cancer, has completed, sponsored by Point Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
13
Study locations

Study Summary

The purpose of this study is to assess the antitumor activity and safety of the combination of talabostat and cisplatin in patients with metastatic melanoma.

Conditions Studied

Melanoma Skin Cancer

Interventions

  • DRUG cisplatin
  • DRUG talabostat (PT-100) tablets

Study Locations (13)

New York

  • NYU School of Medicine - New York
  • Fifth Avenue Medical Healthcare - New York

Texas

  • Mary Crowley Medical Research Center - Dallas
  • Tyler Cancer Center - Tyler

Arkansas

  • University of Arkansas Medical Sciences - Little Rock

California

  • Cancer Institute Medical Group, Inc. - Santa Monica

Colorado

  • University of Colorado Health Sciences Center - Aurora

Florida

  • Cancer Center of Florida - Ocoee

Indiana

  • Indiana Hematology Oncology Consultants - Indianapolis

New Mexico

  • New Mexico Cancer Center Alliance - Albuquerque

Trial Details

FieldValue
Phase Phase 2
Point Therapeutics

7 total trials

What the finished NCT00083252 record still lists

NCT00083252 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which cisplatin is the first listed.

NCT00083252 lists 13 locations in 11 states (New York, Texas, Arkansas).

Frequently Asked Questions

What is clinical trial NCT00083252 about?

NCT00083252 is a clinical study titled "Study of Talabostat and Cisplatin in Advanced Melanoma". The purpose of this study is to assess the antitumor activity and safety of the combination of talabostat and cisplatin in patients with metastatic melanoma.

What is the current status of trial NCT00083252?

This trial is currently completed. It is a Phase 2 study.

What conditions does trial NCT00083252 study?

This clinical trial studies the following conditions: Melanoma, Skin Cancer.

What interventions are being tested in trial NCT00083252?

The interventions under investigation include: cisplatin (DRUG), talabostat (PT-100) tablets (DRUG).

Who is sponsoring clinical trial NCT00083252?

This trial is sponsored by Point Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00083252 being conducted?

This trial has 13 study locations across Arkansas, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00083252, the US trial registry maintained by the National Library of Medicine. NCT00083252 (unsized enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.